002826.SZ

Tibet AIM Pharm. Inc. [002826.SZ] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

002826.SZ Stock Summary

Earnings have grown 18.1% per last year.

The Moving Average Convergence Divergence (MACD) for 002826.SZ recently turned positive (within last 10 days).

In the News

002826.SZ Financial details

Company Rating

Market Cap

1.61B

Income

46.78M

Revenue

803.27M

Book val./share

Cash/share

Dividend

0.1

Dividend %

0.86%

Employees

447

Optionable

Shortable

Yes

Earnings

28 Apr 2021

P/E

49.29

Forward P/E

PEG

42.86

P/S

2.76

P/B

3.06

P/C

P/FCF

29.43

Quick Ratio

2.15

Current Ratio

2.4

Debt / Equity

LT Debt / Equity

EPS (TTM)

0.25

EPS next Y

EPS next Q

EPS this Y

4.55%

EPS next Y

EPS next 5Y

EPS last 5Y

12.09%

Revenue last 5Y

11.88%

Revenue Q/Q

-21.04%

EPS Q/Q

71.33%

SMA20

SMA50

-13.04%

SMA100

33.33%

Inst Own

Inst Trans

ROA

ROE

ROC

0.07%

Gross Margin

47%

Oper. Margin

Profit Margin

Payout

44%

Shs Outstand

Shs Float

Target Price

52W Range

5.57-13.28

52W High

+55.77%

52W Low

+305%

RSI

Rel Volume

0.63

Avg Volume

6.61M

Volume

4.16M

Perf Week

3.32%

Perf Month

5.03%

Perf Quarter

79.2%

Perf Half Y

87.85%

Beta

0.312

Volatility

0.15%, 0.64%

Prev Close

-0.64%

Price

20.25

Change

002826.SZ Financial Performance

002826.SZ Dividend History

002826.SZ Frequently Asked Questions

What is Tibet AIM Pharm. Inc. stock symbol ?

Tibet AIM Pharm. Inc. is a CN stock and trading under the symbol 002826.SZ

What is Tibet AIM Pharm. Inc. stock quote today ?

Tibet AIM Pharm. Inc. stock price is $20.25 today.

Is Tibet AIM Pharm. Inc. stock public?

Yes, Tibet AIM Pharm. Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 6.61M
Market Capitalization 1.61B
Employee 447
CEO Mr. Ke Xu
Headquarters Beijing,CN
IPO Date 2016-12-12
Website https://www.emyy.cn

Tibet AIM Pharm. Inc. engages in the research and development of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain; Carbetocin injections; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotic, antiallergic, and digestive system. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.